Stefanie Corradini

CV
h-index32
4papers
36citations
Novelty26%
AI Score37

4 Papers

2.6CVApr 11
Improving Deep Learning-Based Target Volume Auto-Delineation for Adaptive MR-Guided Radiotherapy in Head and Neck Cancer: Impact of a Volume-Aware Dice Loss

Sogand Beirami, Zahra Esmaeilzadeh, Ahmed Gomaa et al.

Background: Manual delineation of target volumes in head and neck cancer (HNC) remains a significant bottleneck in radiotherapy planning, characterized by high inter-observer variability and time consumption. This study evaluates the integration of a Volume-Aware (VA) Dice loss function into a self-configuring deep learning framework to enhance the auto-segmentation of primary tumors (PT) and metastatic lymph nodes (LN) for adaptive MR-guided radiotherapy. We investigate how volume-sensitive weighting affects the detection of small, anatomically complex nodal metastases compared to conventional loss functions. Methods: Utilizing the HNTS-MRG 2024 dataset, we implemented an nnU-Net ResEnc M architecture. We conducted a multi-label segmentation task, comparing a standard Dice loss baseline against two Volume-Aware configurations: a "Dual Mask" setup (VA loss on both PT and LN) and a "Selective LN Mask" setup (VA loss on LN only). Evaluation metrics included volumetric Dice scores, surface-based metrics (SDS, MSD, HD95), and lesion-wise binary detection sensitivity and precision. Results: The Selective LN Mask configuration achieved the highest LN Volumetric Dice Score (0.758 vs. 0.734 baseline) and significantly improved LN Lesion-Wise Detection Sensitivity (84.93% vs. 81.80%). However, a critical trade-off was observed; PT detection precision declined significantly in the selective setup (63.65% vs. 81.27%). The Dual Mask configuration provided the most balanced performance across both targets, maintaining primary tumor precision at 82.04% while improving LN sensitivity to 83.46%. Conclusions: A volume-sensitive loss function mitigated the under-representation of small metastatic lesions in HNC. While selective weighting yielded the best nodal detection, a dual-mask approach is required in multi-label tasks to maintain segmentation accuracy for larger primary tumor volumes.

MED-PHFeb 24, 2025
SynthRAD2025 Grand Challenge dataset: generating synthetic CTs for radiotherapy

Adrian Thummerer, Erik van der Bijl, Arthur Jr Galapon et al.

Medical imaging is essential in modern radiotherapy, supporting diagnosis, treatment planning, and monitoring. Synthetic imaging, particularly synthetic computed tomography (sCT), is gaining traction in radiotherapy. The SynthRAD2025 dataset and Grand Challenge promote advancements in sCT generation by providing a benchmarking platform for algorithms using cone-beam CT (CBCT) and magnetic resonance imaging (MRI). The dataset includes 2362 cases: 890 MRI-CT and 1472 CBCT-CT pairs from head-and-neck, thoracic, and abdominal cancer patients treated at five European university medical centers (UMC Groningen, UMC Utrecht, Radboud UMC, LMU University Hospital Munich, and University Hospital of Cologne). Data were acquired with diverse scanners and protocols. Pre-processing, including rigid and deformable image registration, ensures high-quality, modality-aligned images. Extensive quality assurance validates image consistency and usability. All imaging data is provided in MetaImage (.mha) format, ensuring compatibility with medical image processing tools. Metadata, including acquisition parameters and registration details, is available in structured CSV files. To maintain dataset integrity, SynthRAD2025 is divided into training (65%), validation (10%), and test (25%) sets. The dataset is accessible at https://doi.org/10.5281/zenodo.14918089 under the SynthRAD2025 collection. This dataset supports benchmarking and the development of synthetic imaging techniques for radiotherapy applications. Use cases include sCT generation for MRI-only and MR-guided photon/proton therapy, CBCT-based dose calculations, and adaptive radiotherapy workflows. By integrating diverse acquisition settings, SynthRAD2025 fosters robust, generalizable image synthesis algorithms, advancing personalized cancer care and adaptive radiotherapy.

CVAug 29, 2025
Benchmarking GPT-5 in Radiation Oncology: Measurable Gains, but Persistent Need for Expert Oversight

Ugur Dinc, Jibak Sarkar, Philipp Schubert et al.

Introduction: Large language models (LLM) have shown great potential in clinical decision support. GPT-5 is a novel LLM system that has been specifically marketed towards oncology use. Methods: Performance was assessed using two complementary benchmarks: (i) the ACR Radiation Oncology In-Training Examination (TXIT, 2021), comprising 300 multiple-choice items, and (ii) a curated set of 60 authentic radiation oncologic vignettes representing diverse disease sites and treatment indications. For the vignette evaluation, GPT-5 was instructed to generate concise therapeutic plans. Four board-certified radiation oncologists rated correctness, comprehensiveness, and hallucinations. Inter-rater reliability was quantified using Fleiss' \k{appa}. Results: On the TXIT benchmark, GPT-5 achieved a mean accuracy of 92.8%, outperforming GPT-4 (78.8%) and GPT-3.5 (62.1%). Domain-specific gains were most pronounced in Dose and Diagnosis. In the vignette evaluation, GPT-5's treatment recommendations were rated highly for correctness (mean 3.24/4, 95% CI: 3.11-3.38) and comprehensiveness (3.59/4, 95% CI: 3.49-3.69). Hallucinations were rare with no case reaching majority consensus for their presence. Inter-rater agreement was low (Fleiss' \k{appa} 0.083 for correctness), reflecting inherent variability in clinical judgment. Errors clustered in complex scenarios requiring precise trial knowledge or detailed clinical adaptation. Discussion: GPT-5 clearly outperformed prior model variants on the radiation oncology multiple-choice benchmark. Although GPT-5 exhibited favorable performance in generating real-world radiation oncology treatment recommendations, correctness ratings indicate room for further improvement. While hallucinations were infrequent, the presence of substantive errors underscores that GPT-5-generated recommendations require rigorous expert oversight before clinical implementation.

CVNov 22, 2025
Large-Scale Pre-training Enables Multimodal AI Differentiation of Radiation Necrosis from Brain Metastasis Progression on Routine MRI

Ahmed Gomaa, Annette Schwarz, Ludwig Singer et al.

Background: Differentiating radiation necrosis (RN) from tumor progression after stereotactic radiosurgery (SRS) remains a critical challenge in brain metastases. While histopathology represents the gold standard, its invasiveness limits feasibility. Conventional supervised deep learning approaches are constrained by scarce biopsy-confirmed training data. Self-supervised learning (SSL) overcomes this by leveraging the growing availability of large-scale unlabeled brain metastases imaging datasets. Methods: In a two-phase deep learning strategy inspired by the foundation model paradigm, a Vision Transformer (ViT) was pre-trained via SSL on 10,167 unlabeled multi-source T1CE MRI sub-volumes. The pre-trained ViT was then fine-tuned for RN classification using a two-channel input (T1CE MRI and segmentation masks) on the public MOLAB dataset (n=109) using 20% of datasets as same-center held-out test set. External validation was performed on a second-center test cohort (n=28). Results: The self-supervised model achieved an AUC of 0.916 on the same-center test set and 0.764 on the second center test set, surpassing the fully supervised ViT (AUC 0.624/0.496; p=0.001/0.008) and radiomics (AUC 0.807/0.691; p=0.005/0.014). Multimodal integration further improved performance (AUC 0.947/0.821; p=0.073/0.001). Attention map visualizations enabled interpretability showing the model focused on clinically relevant lesion subregions. Conclusion: Large-scale pre-training on increasingly available unlabeled brain metastases datasets substantially improves AI model performance. A two-phase multimodal deep learning strategy achieved high accuracy in differentiating radiation necrosis from tumor progression using only routine T1CE MRI and standard clinical data, providing an interpretable, clinically accessible solution that warrants further validation.